Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>Shigella flexneri</i> 2a Strain CVD 1207, with Specific Deletions in <i>virG</i> , <i>sen</i> , <i>set</i> , and <i>guaBA</i> , Is Highly Attenuated in Humans

1 Mar 2000

Abstract excerpt

A phase 1 clinical trial was conducted among 35 healthy adult volunteers to evaluate the safety, immunogenicity, and shedding of different doses of CVD 1207, a live attenuated Shigella flexneri 2a vaccine candidate with specific deletion mutations in virG, sen, set, and guaBA. CVD 1207 retains the ability to invade epithelial cells but cannot effectively spread intercellularly after invasion (DeltavirG), does not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Escherichia coli research studies
Share to Salmonella and Campylobacter epidemiology
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 10678904
DOI: 10.1128/iai.68.3.1034-1039.2000

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>Shigella flexneri</i> 2a Strain CVD 1207, with Specific Deletions in <i>virG</i> , <i>sen</i> , <i>set</i> , and <i>guaBA</i> , Is Highly Attenuated in HumansPMID 10678904Read ↗

Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.Semantic proximity Read ↗

Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccineSemantic proximity Read ↗

Vaccination against Shigellosis with Attenuated <i>Shigella flexneri</i> 2a Strain SC602Semantic proximity Read ↗

Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult SubjectsSemantic proximity Read ↗

Towards establishing a correlate of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei 1790GAHB GMMA investigational vaccineSemantic proximity Read ↗

Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.Semantic proximity Read ↗

Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protectionSemantic proximity Read ↗

Status of vaccine research and development for ShigellaSemantic proximity Read ↗

Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum.Semantic proximity Read ↗

Towards establishing correlates of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) candidate vaccine (1790GAHB).Semantic proximity Read ↗

A broad spectrum Shigella vaccine based on VirG53–353 multiepitope region produced in a cell-free systemSemantic proximity Read ↗

Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity scoreSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.